Lilly’s Mirror Portfolio Marks Milestone

Eli Lilly has announced that its Mirror Portfolio, a concept created for innovation being developed outside the company, has acquired two molecules.

A venture capital firm involved in Lilly’s Mirror Portfolio has acquired two molecules and will oversee further development. The Mirror Portfolio, which is a concept created by Lilly, aims to access innovation developed outside the company.

The first of the two molecules is a molecule developed at a major academic institution that is being studied as a potential treatment for congestive heart failure. The second molecule, developed by Lilly, is being studied for its potential in bone healing and cancer. Chorus, Lilly’s virtual development organization, will conduct the studies for the two molecules at the companies’ direction.